Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622972		
Filing Date		2003-07-18		
First Named Inventor Russ Art Unit Examiner Name Ilwoo		sell Mark Earnes		
		2182		
		Park		
Attorney Docket Numi	per	MS303380.01 / 5059		

	Remove							
Examiner Initial*	Cite No	Patent Number Nind Issue Date Name of Patentee of Applicant Relev		Releva	ages,Columns,Lines where elevant Passages or Relevant igures Appear			
	1	6118450		2000-09-12	19-12 Proehl et al.			
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document		Lines where les or Relevant	
	1	20020041692	A1	2002-04-11	Seto et al.			
	2	20020059584	A1	2002-05-16 Forman et al.				
	3	20020113824	A1	2002-08-22	Myers			
	4	20030135513	A1	2003-07-17	Quinn et al.			
	5	20030236582	A1	2003-12-25	Zamir et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622972		
Filing Date		2003-07-18		
First Named Inventor Russ		ell Mark Earnes		
Art Unit		2182		
Examiner Name Ilwoo		Park		
Attorney Docket Number		MS303380.01 / 5059		

Date Considered

	6	20040017997	A1	2004-0	1-29	Cowgill				
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
				FORE	GN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1									
If you wis	h to a	d additional Foreign P	atent Do	cument	citation	information p	lease click the Add	buttor	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initials* Cite (Cook, Initials) (Cook, Init									ТБ	
1										
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									

EXAMINER SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10622972
Filing Date		2003-07-18
First Named Inventor Russ		ell Mark Earnes
Art Unit		2182
Examiner Name	Ilwoo	Park
Attorney Docket Number		MS303380.01 / 5059

CERTIFICATION STATEMENT

Please see	37	CFR	1.97	and	1 98	to make	the	appropriate	selection(s)	r

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a deepin patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to or individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. Set OFCR 1.57(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Brian P. Klein/	Date (YYYY-MM-DD)	2006-06-01
Name/Print	Brian P. Klein	Registration Number	44837

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 Card 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.211-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the principal principal

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as and of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4U S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of the
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.